VanEck Pharmaceutical ETF
PPH
91 hedge funds and large institutions have $346M invested in VanEck Pharmaceutical ETF in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 8 reducing their positions, and 10 closing their positions.
392% more capital invested
Capital invested by funds: $70.5M → $346M (+$276M)
338% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 8
317% more call options, than puts
Call options by funds: $4.83M | Put options by funds: $1.16M
170% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
45.3% more ownership
Funds ownership: 19.22% → 64.52% (+45%)
21% more funds holding
Funds holding: 75 → 91 (+16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$164M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$37.6M |
| 3 |
Goldman Sachs
New York
|
+$16.6M |
| 4 |
Morgan Stanley
New York
|
+$11.5M |
| 5 |
NC
Noked Capital
Tel Aviv,
Israel
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$2.77M |
| 2 |
LJAC
L.J. Altfest & Co
New York
|
-$1.42M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$946K |
| 4 |
GA
GFS Advisors
Houston,
Texas
|
-$518K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$504K |
PPH Hedge Fund Activity: Q2 2022 in Review
91 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2022, worth a combined $346M — up 392% from $70.5M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PPH positions and 10 closed out — a net gain of 17 holders — while 35 added to existing stakes and 8 trimmed.
The largest buyer was Phoenix Financial, adding an estimated $164M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $2.77M sold.
- 91 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2022, up from 75 in Q1 2022.
- Funds reported $346M of VanEck Pharmaceutical ETF stock for Q2 2022, up 392% quarter-over-quarter.
- 27 funds opened new VanEck Pharmaceutical ETF positions in Q2 2022 and 10 closed out, a net change of +17 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2022 was Phoenix Financial, an estimated $164M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2022 was Clough Capital Partners, an estimated $2.77M sold.
Based on aggregated 13F filings for Q2 2022.